- * Participants with chronic heart failure clinically indicated to receive spironolactone therapy, aged 18 years or older with serum potassium level of 4.3 - 5.1 mEq/L at screening and baseline, AND (1) chronic kidney disease (GFR \< 60 mL/min) OR (2) documented history of hyperkalemia within the last 6 months
- * Females of child-bearing potential must be non-lactating, must have a negative serum pregnancy test at screening, and must have used a highly effective form of contraception for at least 3 months before study drug administration, during the study, and for one month after study completion
- * Male participants and/or their female partners of child-bearing potential must use a highly effective form of contraception during the study and for 3 months after study completion
- * Must sign informed consent document
Hyperkalemia
Evaluation of Patiromer in Heart Failure Patients
NCT00868439 | PHASE 2 | INTERVENTIONAL
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Investigator Site
Miami,Florida,United States,33176
Investigator Site
Port Charlotte,Florida,United States,33952
Investigator Site
Peoria,Illinois,United States,61606
Investigator Site
Minneapolis,Minnesota,United States,55417
Investigator Site
Buffalo,New York,United States,14215
Investigator Site
Northport,New York,United States,11768
Investigator Site
Columbus,Ohio,United States,43210
Investigator Site
Dallas,Texas,United States,75216
Investigator Site
Salt Lake City,Utah,United States,84124
Investigator Site
Brno,Czechia,62500
Investigator Site
Prague,Czechia,12008
Investigator Site
Prague,Czechia,14021
Investigator Site
Tbilisi,Georgia,0102
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0164
Investigator Site
Tbilisi,Georgia,0179
Investigator Site
Gottingen,Germany,37075
Investigator Site
Heidelberg,Germany,69120
Investigator Site
Warsaw,Poland,02637
Investigator Site
Barnaul,Russian Federation,656099
Investigator Site
Kemerovo,Russian Federation,650002
Investigator Site
Moscow,Russian Federation,111020
Investigator Site
Moscow,Russian Federation,111539
Investigator Site
Moscow,Russian Federation,129301
Investigator Site
St Petersburg,Russian Federation,197341
Investigator Site
St Petersburg,Russian Federation,198205
Investigator Site
St Petersburg,Russian Federation,199106
Investigator Site
Dnipropetrovsk,Ukraine,49023
Investigator Site
Kharkiv,Ukraine,61018
Investigator Site
Kharkiv,Ukraine,61176
Investigator Site
Kiev,Ukraine,03680
Investigator Site
Kiev,Ukraine,03680
Investigator Site
Kiev,Ukraine,04114
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov